Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
In this trial, treatment efficacy and safety of Poziotinib will be assessed in patients with
stage IV lung adenocarcinoma harboring HER2 mutation.
Phase:
Phase 2
Details
Lead Sponsor:
Korean Association for the Study of Targeted Therapy
Collaborators:
Chonnam National University Hospital Chungnam National University Hospital Konkuk University Medical Center Kosin University Gospel Hospital Kyungpook National University Kyungpook National University Hospital